BBD Biophenix

Biobide signs a contract with the U.S. National Institute of Environmental Health Sciences (NIH-NIEHS)

This project will analyze the toxicological impact of exposure to 30 chemical compounds using zebrafish as animal model.

The NIEHS is one of the 27 Institutes and Centers composing the US-National Institutes of Health.

January 25, 2016. BBD BioPhenix-Biobide (now part of Bionaturis Group), has recently signed a contract agreement with one of the U.S. National Institutes of Health, the National Institute of Environmental Health Sciences (NIH-NIEHS), for analyzing the impact of exposure to different chemicals with unknown toxicological potential in zebrafish embryos. Biobide provides zebrafish-based services in the preclinical area, mainly toxicology, through early detection of adverse effects in a Good Laboratory Practice (GLP) setting.

Biobide will perform the assessment of bioavailability and toxicity in zebrafish embryos following exposure to 30 compounds with potential for various adverse effects, providing high content screening information on multiple target organs using a GLP-environment.

This contract agreement between Biobide and one of the main Institutions of Public Health in the USA, the NIH, is the result of years of preparation and study. BBD BioPhenix-Biobide, is one of the recognized zebrafish resource institutions worldwide. “This contract agreement becomes relevant because it may facilitate future collaborations with this prestigious institution”, the R&D Management Director at the company, Arantza Muriana, has stated.

The collaboration between Biobide and the NIH-NIEHS started last year when they collaborated in a project to study the toxicity of several flame retardants found in everyday household products, such as utensils, upholstery and furniture, to which people, and most importantly babies and young children, are regularly exposed.  Biobide and the NIH-NIEHS utilized the versatility of the zebrafish model to evaluate the toxicity of environmental compounds with the main goal of the assay being the reduction or prevention of the use of such […]

January 25th, 2016|Blog english, Press Releases|Comments Off|

August Newsletter

If you want to know Bionaturis Group latest news, here you are our August Newsletter


Bionaturis and Covap join forces to increase productivity in livestock


The Journal of Biological Chemistry publishes the result of a research by BBD BioPhenix


Let’s get to know…

Blanca Díaz de Otalora Uriarte, 41 years old, born in San Sebastian, Degree in Business Managment at Basque Country University.


-When you were a child, what did you want to be as an adult?
A nurse.
-What do you like the most about your job?
Making it well.
-What are your future challenges?
Involving myself more in the managment of incentives and improving day a day.
-Your favourite dish
Fried eggs with chips and iberian ham.
-A place
San Sebastian.
-A film
‘Instructions not included’, by Eugenio Derbez.
-A historical figure
Eleanor of Aquitaine.
-A book
‘Amaya or the basques in 8th Century’, by Navarro Villoslada.
-A song
‘La chica de ayer’, by Nacha Pop.
-What do you usually do in your free time?
Being with my family and friends, going to the beach, to the mountains…
-You can’t live without…
My family.
-How do you imagine the world in 20 years?
I hope it will be better.

  Blanca has been working as an assistant to Managment in BBD BioPhenix (Bionaturis Group) since June, 2014.

Bionaturis and Covap join forces to increase productivity in livestock

Corporacion Tecnologica de Andalucia (CTA) has granted the Company with an incentive worth of €147.027,46 to partially fund the Bovihealth project. The initiative aims the development of peptides to be used as health and growth promoter in cattle. The Company partners up in this project with an end-user of the seek products, the Cooperativa del Valle de los Pedroches (COVAP). The incentive is completely subsidized by the Regional Andalusian Government and the Ministry of Economy and Competitiveness of Spain. “With this initiative we […]

August 11th, 2015|Blog english|Comments Off|

The Journal of Biological Chemistry publishes the result of a research by BBD BioPhenix

Researchers of BBD BioPhenix-Biobide, company integrated in Bionaturis Group, has made an study for the pharmaceutical laboratory Sanofi in order to help them to confirm that some proteins present in hypoxic cells have an important function in the tumor growth. The result of the essay has recently been published in the well-regarded specialized magazine ‘The Journal of Biological Chemistry’.

The formation of new vessels in the tumor (angiogenesis) is essential for primary tumor growth and facilitates tumor invasion and metastasis. Hypoxia has been described as one trigger of angiogenesis. Indeed, hypoxia is a hallmark of solid tumors and has profound effects on the different components of the tumoral environment. For example, hypoxia is able to activate endothelial cells, leading to angiogenesis. In this study, they were identified some proteins involved in the hypoxia correlated with tumors, and the function of the identified sialoglycoproteins was assessed in a vasculogenesis assay in vivo in zebrafish by using morpholinos.

For further information, please click here

July 29th, 2015|Blog english|Comments Off|

July Newsletter

If you want to know Bionaturis Group latest news, here you are our July Newsletter


Bionaturis signs a strategic agreement for its corporate expansion in China

The company and the US-Biotech company BMI will develop jointly human and animal vaccines

BBD BioPhenix sets up a subsidiary in USA

Bionaturis Group consolidates its international scope in 2015 Bio Convention


Let’s get to know…

Francisco Jose Fernandez-Trujillo Nuñez, 54 years old, born in Cadiz. PhD in Medicine and Surgery and teacher of Neuroanatomy at Cadiz University.


-When you were a child, what did you want to be as an adult?
Older, a naval officer, an architect, a doctor… except a bullfighter and a fireman, I think nearly anything.
-What do you like the most about your job?
I like to assist in implementing changes in the working environment of the company, changes led by the people of the team to which I assist in this challenge.
-What are your future challenges?
I usually do not set long-term goals for myself. My current challenge is Bionaturis Jerez. I think one can not easily foresee future opportunities.
-Your favourite dish
A stew with artichokes with peas, broad bean and good olive oil.
-A place
Any place where the sunset is by the sea.
-A film
‘Star War’. I don’t know how many times I have watched it and it always seems new for me.
-A historical figure
Due to my academic background, Charles Darwin.
-A book
Although it seems a classical answer, ‘The Ingenious Gentleman Don Quixote of La Mancha’. In my small way, I am a collector of editions of this book.
-A song
‘Águas de março’, by Antonio Carlos Jobim, and the version by Ivano Fossati, ‘La Pioggia Di Marzo’.
-What do you usually do in your free time?
Reading, watching cinema and enjoying with friends.
-You can’t live without…
My family.
-How […]

July 14th, 2015|Blog english|Comments Off|

Bionaturis Group consolidates its international scope in 2015 Bio Convention

Bionaturis and BBD BioPhenix – the two companies that comprise the Bionaturis Group -  have solidified their international scope in the latest edition of the Bio Convention, held this year in Philadelphia and considered an annual landmark in the worldwide biotech sector. During the event, our delegates engaged in significant one-on-one meetings with current and future customers demonstrating the increasing interest in the Group.

Bionaturis Development Area Manager, Dr. Juan Jose Infante; BBD BioPhenix General Manager, Mr. Andoni Cruz; and the Global Sales Manager, Mr. Eli Kehrli, were the Group’s delegates at the most important global biotech event of the year which brings together more than 15,000 biotech companies from 65 different countries.

The main goals of Bionaturis were focused on the consolidation and monitoring of current customers and in establishing new contacts with future customers and partners. In human health, Bionaturis progressed in its collaboration with BMI, a strategic partner in the US, for the joint development and manufacture of a recently validated antiviral vaccine technology on the Groups expression platform, Flylife. In animal health, Bionaturis’ delegates, Dr. Infante and Mr. Kehrli, held bilateral meetings with the business development managers of the largest multinational vet companies that represented both current customers as well as potential future collaborators. During these meetings, they dealt with key issues for the licensing of products currently in Bionaturis’ portfolio.

According to Dr. Infante, “with a more and more complete portfolio, our potential partners can find in Bionaturis Group a wide variety of possibilities that positions Bionaturis Group as the perfect partner in the development of biological medicines for both human and animal health. Being conscious of the changing requirements of the market, our business model adapts perfectly to the needs of […]

June 29th, 2015|Blog english, congress|Comments Off|

Bionaturis Group will attend the BIO International Convention 2015 in Philadelphia

Bionaturis Group, represented by BBD BioPhenix and Bionaturis, will participate one more year in the most important Biotechnology event in the world: the BIO International Convention 2015, taking place in Philadelphia (USA) on 15th-18th of June. Bionaturis CSO, Juan Jose Infante, and the General Manager of BBD BioPhenix, Andoni Cruz, will be the group delegates in this relevant meeting organized by the Biotechnology Industry Organization (BIO).

Several weeks before the event, Bionaturis Group has closed several one to one meetings with current partners and future customers. In the last edition of this international forum, more than 29,000 one-to-one meetings were celebrated among 3,100 companies from more than 70 different countries. In addition of its participation in the partnering sessions, Bionaturis Group will exhibit a booth regarding BBD BioPhenix activities within the space assigned to BioBasque, in the Spanish Pavillion.

If you want to arrange a meeting with Bionaturis Group delegates in the BIO International Convention 2015, please write an email to

For further information about the event, plase click here

About Bionaturis Group

The Bionaturis Group offers cutting-edge biotechnological products and services for human and animal health. Considered an international benchmark in the vaccines research, Bionaturis Group closed last exercise with an increase of sales of 73% and a positive EBITDA of 29% compared to the previous year. The biotechnological Group which envisages a global access to health, is listed on the Spanish Stock Exchange for SMEs (ticker BNT).


June 11th, 2015|Blog english, congress|Comments Off|

Bionaturis Group, in the 14th Annual World Preclinical Congress in Boston

BBD BioPhenix–Biobide, subsidiary of Bionaturis Group, is attending this week the 14th Annual World Preclinical Congress, a prestigious international meeting hold in June 10-12th in Boston (USA). The R&D Management Director of the Company based in San Sebastian, Arantza Muriana, is attending this relevant forum, devoted to preclinical research and the challenges and opportunities in early drug discovery and development. This meeting brings together outstanding companies and scientists in the world to deal with the latest topics in pharmaceutical Biotechnology, which means a great chance to show the board services portfolio of BBD BioPhenix-Biobide and Bionaturis Group to future customers and partners.

For further information about the event, please click here

The presence of Bionaturis Group in this forum is included in its international expansion with effective presence in the American continent. Besides this forum, BBD BioPhenix-Biobide and Bionaturis will attend shortly other international events, such as the Bio Convention, also in the USA.

About Bionaturis Group

Bionaturis Group is a Spanish biopharmaceutical Company, listing in Madrid on the Alternative Equity Market (MAB) since 2012, with a core business focus in the investigation, development and production of biotechnological solutions in order to improve the global health access for persons and animals. Bionaturis has production facilities in Jerez (Cadiz) and San Sebastian (Basque Country) as well as commercial agreements in China and Latam.

June 10th, 2015|Blog english, congress|Comments Off|

Bionaturis Group takes part in the European Forum for the Innovation in the Marine Bioresources

Bionaturis Group took part recently in the final event of the European Forum for the innovation in the Marine Bioresources AtlanticBlueTech Project, hold in CEEI Bahia de Cadiz. Representatives of the institutions and companies included in the project from Portugal, United Kingdom and Ireland, among other countries, attended this top-level international forum.

Ana de las Heras, PhD in Veterinarian Sciences and Project Manager at Bionaturis, was the person in charge of explaining the work of the company and the advantages of our platform Flylife for the development and production of biological medicines. In addition, a group of members of Oceano XXI (Cluster do Mar in Portugal, partners of Atlantic BlueTech Project) visited Bionaturis’ facilities in Jerez to know at firsthand how the company is applying innovation in this field.

Bionaturis Group is a Spanish biopharmaceutical Group, listing in Madrid on the Alternative Stock Exchange Market (MAB) since 2012, focusing its activity on the research, development and manufacturing of cutting-edge biotechnological solutions in order to improve a global access to health for people and animals. Besides its production platform in Jerez (Spain), Bionaturis Group has other acquired company in Spain (BBD BioPhenix) and it is nowadays in the springboard of its international expansion in Asia and Latam.

If you want more information about the event, please click here

(Photos by courtesy of Oceano XXI)

May 14th, 2015|Blog english, congress|Comments Off|

Bionaturis Group increased 29% EBITDA in full year 2014 results

The Spanish Biotechnological increases 152% its Net Income.
Group’s Earning before Interest and Taxes raised in 2014 386%, to reach €756.000, compared with the €156.000 registered in the past year.
Bionaturis Group reported revenue in full year 2014 soars to €3.03 million, an increase of 73% compared with last year.

Bionaturis Group, Spanish biopharmaceutical Group (ticker BNT) focusing its activity on the development of biological medicines for human and animal health, has reached in year 2014 €931.000 of EBITDA in full year 2014 results, increased of 29% compared with last year. Bionaturis Group Net Income was €1.19 million in 2014, a growth of 152 % compared to the same period of the previous year.

Furthermore, the total amount of income was €3.03 million, which means an increase of 73% compared to the last year. This increase is basically due to the rise of net sales in 116% compared to 2013.

2014 has been the first year consolidating the figures of BBD Biophenix, company specialized in advanced systems of drug discovery  acquired last May, 2014. A strategic acquisition for Bionaturis to support its growth and international expansion, at the time that contributes to its vision of facilitating industry the drug development process. With this transaction, Bionaturis extends its international presence and multinational customers portfolio, such as, Sanofi, Roche, Servier and Royal Dutch Shell Group, among others.

Performance evolution for business areas

The evolution of Bionaturis Group’s business divisions have been aligned with the foreseen. In this regard, the human and animal health area has extended throughout 2014 the collaborative developments with third parties (BNTs) and has reached important milestones as the beginning of collaboration programs in human health with two US-based biotech Companies.

Meanwhile, the CRO division (Contract Research Organization), included BBD Biophenix, […]

May 1st, 2015|Blog english, Hechos Relevantes, Press Releases|Comments Off|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.